Tissue Diagnostics Market Growth, Size, Trends Analysis - By Technology, By Application, By Modality, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Description

Tissue Diagnostics Market Introduction and Overview

According to SPER market research, 'Global Tissue Diagnostics Market Size- By Technology, By Application, By Modality, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Tissue Diagnostics Market is predicted to reach 20.08 Billion by 2034 with a CAGR of 8.7%.

Tissue diagnostics is a medical practice that examines tissue samples for signs of disease, particularly cancer. It involves looking at tissue biopsies under a microscope to find abnormal cells and determine their characteristics, often using specific staining methods. This process enables precise disease identification, staging, and assessment of a tumor's prospective response to particular therapy. Technological developments like as digital pathology, genetic profiling, and biomarker analysis have greatly improved the accuracy and efficacy of tissue diagnostics by enabling early detection and customized treatment plans.

Restraints: One of the biggest challenges for organizations launching novel tissue diagnostic technologies is navigating regulatory environments. The FDA's stringent approval procedure poses a significant obstacle, especially for Class III devices that need premarket approval. Current guideline documents make things considerably more difficult by requiring 510(k) submissions for even small device modifications. Similarly, tight requirements for CE Marking are enforced by the EU's Medical Device and In Vitro Diagnostic Device Regulations.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Technology, By Application, By Modality, By End Use.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Abbott Laboratories, Agilent Technologies, BD, Bio SB, BioGenex, bioMerieux SA, Cell Signaling Technology, Inc., Danaher, DiaGenic ASA, F. Hoffmann-La Roche Ltd., GE Healthcare, Merck KGaA, QIAGEN, and Others.

Tissue Diagnostics Market Segmentation:

By Technology: Based on the Technology, Global Tissue Diagnostics Market is segmented as; Immunohistochemistry, In Situ Hybridization, Primary & Special Staining, Digital Pathology and Workflow, Anatomic Pathology, Molecular Pathology.

By Application: Based on the Application, Global Tissue Diagnostics Market is segmented as; Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Gastric Cancer, Other Cancers.

By Modality: Based on the Modality, Global Tissue Diagnostics Market is segmented as; Clinical, Pharma / CRO / Research Market.

By End Use: Based on the End Use, Global Tissue Diagnostics Market is segmented as; (Hospitals, Diagnostic Center, Pharmaceutical Organizations, Contract Research Organizations (CROs).

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Product Code: HLCA2564

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Tissue Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Tissue Diagnostics Market

7. Global Tissue Diagnostics Market, By Technology, (USD Million) 2021-2034

7.1. Immunohistochemistry
7.2. In Situ Hybridization
7.3. Primary & Special Staining
7.4. Digital Pathology and Workflow
7.5. Anatomic Pathology
7.6. Molecular Pathology

8. Global Tissue Diagnostics Market, By Application, (USD Million) 2021-2034

8.1. Breast Cancer
8.2. Non-small Cell Lung Cancer
8.3. Prostate Cancer
8.4. Gastric Cancer
8.5. Other Cancers

9. Global Tissue Diagnostics Market, By Modality, (USD Million) 2021-2034

9.1. Clinical
9.2. Pharma / CRO / Research Market

10. Global Tissue Diagnostics Market, By End Use, (USD Million) 2021-2034

10.1. Hospitals
10.2. Diagnostic Center
10.3. Pharmaceutical Organizations
10.4. Contract Research Organizations (CROs)

11. Global Tissue Diagnostics Market, (USD Million) 2021-2034

11.1. Global Tissue Diagnostics Market Size and Market Share

12. Global Tissue Diagnostics Market, By Region, (USD Million) 2021-2034

12.1. Asia-Pacific
- 12.1.1. Australia
- 12.1.2. China
- 12.1.3. India
- 12.1.4. Japan
- 12.1.5. South Korea
- 12.1.6. Rest of Asia-Pacific
12.2. Europe
- 12.2.1. France
- 12.2.2. Germany
- 12.2.3. Italy
- 12.2.4. Spain
- 12.2.5. United Kingdom
- 12.2.6. Rest of Europe
12.3. Middle East and Africa
- 12.3.1. Kingdom of Saudi Arabia
- 12.3.2. United Arab Emirates
- 12.3.3. Qatar
- 12.3.4. South Africa
- 12.3.5. Egypt
- 12.3.6. Morocco
- 12.3.7. Nigeria
- 12.3.8. Rest of Middle-East and Africa
12.4. North America
- 12.4.1. Canada
- 12.4.2. Mexico
- 12.4.3. United States
12.5. Latin America
- 12.5.1. Argentina
- 12.5.2. Brazil
- 12.5.3. Rest of Latin America

13. Company Profile

13.1. Abbott Laboratories
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Agilent Technologies
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. BD
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Bio SB
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. BioGenex
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. bioMerieux SA
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Cell Signaling Technology, Inc.
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Danaher
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. DiaGenic ASA
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. F. Hoffmann-La Roche Ltd.
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. GE Healthcare
- 13.11.1. Company details
- 13.11.2. Financial outlook
- 13.11.3. Product summary
- 13.11.4. Recent developments
13.12. Merck KGaA
- 13.12.1. Company details
- 13.12.2. Financial outlook
- 13.12.3. Product summary
- 13.12.4. Recent developments
13.13. QIAGEN
- 13.13.1. Company details
- 13.13.2. Financial outlook
- 13.13.3. Product summary
- 13.13.4. Recent developments
13.14. Others